The TNFR2-Fc therapeutic, etanercept, has limited efficacy toward TRAPS, demonstrating that the interactions between TNF and its receptors is not the basis of the disease. The gene discussed is TNF; the disease is TNF receptor 1-associated periodic fever syndrome.